Although the anti-tumor activity of venetoclax was demonstrated across a panel of B-NHL cell lines, cell lines with high BCL-2 protein expression were significantly more sensitive to venetoclax compared to those with low BCL-2 protein expression [93]. This evidence concerns the gene BCL2 and neoplasm.